Welcome to IthaMaps

IthaMaps is a global epidemiology database of heamoglobinopathies, illustrating published data on a dynamic global to regional map. Country-specific information on haemoglobinopathy-related policies, prevalence, incidence and overall disease burden is given, including relative allele frequencies of specific globin mutations in each country and/or region, dynamically linked to corresponding IthaGenes entries.

IthaMaps content was supported by partnership with the HVP Global Globin 2020 Challenge

Search

Search Country: OR Search for:  Show organisations

  General information for Algeria


Algeria
Continent: Africa
Capital: Algiers
Population: 34586184
Area (in sq km): 2381740.0

Haemoglobinopathy-specific healthcare policy information for Algeria

Healthcare policyComment/InfoReference
Prevention programme: NoNo carrier screening programme [From: 2nd MEGMA Conference Proceedings].
SCD newborn screening: NoFrom: 2nd MEGMA Conference Proceedings.
Prenatal screening: NoFrom: 2nd MEGMA Conference Proceedings.
Rare disease patient registry: Nohttp://africa-rare.org/
Blood transfusion availability: NoFrom: https://doi.org/10.1182/blood-2018-99-112812
Iron chelation availability: NoMainly deferoxamine or deferasirox type monotherapy. From: https://doi.org/10.1182/blood-2018-99-112812
MRI facilities: NoCardiac and hepatic MRI available to a small number of patients. From: https://doi.org/10.1182/blood-2018-99-112812
Patient associations: Yes (National)Association “EL AMANI” des DES Anémies Hémolytiques Congénitales.

  Prevalence and incidence of major haemoglobinopathies in Algeria

HaemoglobinopathyComment/InfoReference
Prevalence of β-thalassaemia carriers: 2 % of the population[PMID: 24672827]
Prevalence of sickle cell disease carriers: 1.25 % of the population[PMID: 24672827]
Prevalence of α-thalassaemia carriers: 4.6 % of the population[PMID: 23224852]
Prevalence of Hb C carriers: 0.4 % of the population[PMID: 21415987]
Expected incidence of β-thalassaemia: 61 expected affected births/year[PMID: 24672827]
Expected incidence of sickle cell disease: 100 expected affected births/year[PMID: 24672827]
Incidence of sickle cell disease: 191 affected births/yearMedian value estimated using statistical model and demographic data.[PMID: 23103089]
Known β-thalassaemia patients: 3000 patients[PMID: 24672827]
Known sickle cell disease patients: 4711 patients[PMID: 24672827]

  Global Burden of Disease data for Algeria

  Migration data for Algeria

Mutation frequencies in Algeria

 Overview (most frequent mutations with their observed average values and range)

 β-locus

CD 39 CAG>TAG [Gln>STOP]: 29.9 % (25.9 % – 33.9 %)IVS I-110 G>A: 22.85 % (19.3 % – 26.4 %)
CD 6 -A: 12.1 % (11.3 % – 12.9 %)IVS I-1 G>A: 8.6 % (8.1 % – 9.1 %)

 Detailed mutation frequencies

Entry IDLocusRegionEthnic GroupPopulation TypeSample SizeStudy period (from)Study period (to)ReferenceComments
23257β-locusOranAlgerianPatients6219947928377Frequencies are shown for beta-globin gene mutations and are representative of the Oranese population in Algeria (West).
23258β-locusCountry-wideAlgerianPatients208200919205970Frequencies are shown for beta-globin gene mutations. Study samples were acquired from hospitals in Algiers and Kabylia, and originated mostly from the center of the country.

  Organisations in Algeria

Organisations in Algeria are currently not available

 Microattributions

No microattibutions were provided for Algeria. Please contact us, if you are willing to review existing information or provide new data.

To provide new epidemiological information and/or report mistakes, please register/log in first or use the Contact Us form.

Important Note: The relative allele frequencies presented in IthaMaps are not calculated by ITHANET, but they are extracted from the corresponding publications. ITHANET is not responsible for any mistakes in the data. Please use this information with caution! We encourage scientists that have more detailed or updated epidemiological information to contact us.

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaMaps are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.